Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lintuzumab Ac-225 - Actinium Pharmaceuticals

Drug Profile

Lintuzumab Ac-225 - Actinium Pharmaceuticals

Alternative Names: 225Ac-HuM-195; 225Ac-lintuzumab; Ac-225-Lintuzumab; AC225 MOAB M195; Ac225 monoclonal antibody M195; Actimab-A; Actimab-M; Actimab-MDS; Actinium-225 (225Ac)-Lintuzumab; Actinium-225-labelled HuM195; HuM195-Ac-225

Latest Information Update: 18 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDL BioPharma
  • Developer Actinium Pharmaceuticals; Baylor Research Institute; Memorial Sloan-Kettering Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 03 Apr 2019 Pharmacodynamics data from a preclinical trial in Acute Myeloid Leukaemia released by Actinium Pharmaceuticals
  • 29 Mar 2019 Pharmacodynamics data from preclinical trials in Acute myeloid leukaemia presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
  • 20 Mar 2019 Actinium Pharmaceuticals files for patent protection for lintuzumab Ac-225 (in combination with venetoclax or BCL-2 inhibitors as a method to treat cancer)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top